Floatz logo

Tenalisib

Lymphoma, T-Cell, Cutaneous

Rhizen Pharmaceuticals SASmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Lymphoma, T-Cell, Cutaneous cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Tenalisib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
60 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →